Myriad Genetics Inc（MYGN）の財務MYGNMyriad Genetics Inc

Myriad Genetics, Inc. (MYGN) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Hereditary Cancer, accounting for 59.8% of total sales, equivalent to $114.10M. Other significant revenue streams include Prenatal and Pharmacogenomics. Understanding this composition is critical for investors evaluating how MYGN navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, Myriad Genetics, Inc. maintains a gross margin of 66.60%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -20.40%, while the net margin is -22.65%. These profitability ratios, combined with a Return on Equity (ROE) of -32.54%, provide a clear picture of how effectively MYGN converts its operational activities into shareholder value.

In the context of the broader market, MYGN competes directly with industry leaders such as OFIX and SI. With a market capitalization of $529.90M, it holds a leading position in the sector. When comparing efficiency, MYGN's gross margin of 66.60% stands against OFIX's 69.55% and SI's 71.81%. Such benchmarking helps identify whether Myriad Genetics, Inc. is trading at a premium or discount relative to its financial performance.

Myriad Genetics has reported a gross margin of 66.60% for Q2 2026, which is relatively strong, but the company continues to face significant net income losses, with a net income of -43.2 million USD in Q2 2026 and a year-to-date change of -35.18%.